Welcome to our dedicated page for QHSLab SEC filings (Ticker: USAQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
QHSLab, Inc. filings document a Nevada digital health issuer with Section 12(g) common stock traded under USAQ and no registered national exchange listing. Recent Form 8-K reports furnish Regulation FD press-release disclosures on Integrated Service Program growth, Q-Connect assessment launches, unaudited financial updates, fiscal results, and governance initiatives.
The company's material-event filings also record capital-structure transactions, including private placements of common stock and warrants, promissory note modifications, partial conversions, note repurchases, debt cancellation, and related unregistered sales of equity securities. These disclosures outline how QHSLab reports its financing activity, outstanding note obligations, common-stock issuance, and balance-sheet simplification alongside its digital health operating updates.
QHSLab, Inc. filed a current report describing its participation in the Planet MicroCap Las Vegas 2026 conference at the Bellagio, held on June 16-18, 2026. Company representatives will give a corporate presentation, furnished as Exhibit 99.1, and hold one-on-one meetings with various professional and high-net-worth investors.
The presentations will cover QHSLab’s business, strategy, products, market opportunity, growth initiatives, and financial performance, with the goal of increasing investor awareness. The information in Item 7.01, including Exhibit 99.1, is furnished under Regulation FD and is not deemed filed or incorporated into other securities law filings except by specific reference.
QHSLab also highlights that it uses its website and several social media channels, including Twitter/X, LinkedIn, Facebook, and Instagram, to share information that may be considered material, encouraging investors to follow these outlets for updates.
QHSLab, Inc. shared a shareholder update highlighting strong recent operating trends and growth initiatives. Unaudited revenue for April 2026 was approximately $325,889, up from $207,538 in April 2025, representing about 57% year-over-year growth, driven by increasing use of its digital medicine platform and integrated service program.
The Company introduced the QHS Practice Access Network (PAN), a nationwide independent representative program intended to accelerate adoption of its Q-Connect platform by leveraging existing healthcare relationships for warm introductions to physician practices. QHSLab also plans to present at the 2026 Planet MicroCap Showcase on June 16–18, 2026, to expand investor awareness of its digital health strategy.
QHSLab, Inc. reports Q1 2026 results with revenue of $728,685, up from $645,419 a year earlier, and a net loss of $103,906. Growth was driven by its Integrated Service Program, whose revenue more than doubled year over year.
Gross profit rose to $470,803, though gross margin slipped from 66.6% to 64.6% as newer service offerings carry higher delivery costs. Cash was $362,088 against current liabilities of $368,005, and operating activities used $200,242 in cash for the quarter.
The company ended the period with an accumulated deficit of $4,007,457 and explicitly states that these losses and its revenue level raise substantial doubt about its ability to continue as a going concern without improved cash flow or additional financing.
QHSLab, Inc. (USAQ) reported the beneficial ownership of a large shareholder through a Form 3 filing. The Marvin Smollar Family Trust dtd 2/13/2023 is identified as a ten percent owner with 2,226,280 shares of Common Stock held indirectly. This filing records an existing ownership position rather than a new purchase or sale.
QHSLab, Inc. shareholder Marvin Smollar Family Trust filed a Schedule 13D reporting beneficial ownership of 2,226,280 common shares, or about 14.8% of the company. The trust is an irrevocable estate-settlement vehicle administered by co-trustees Justin and Jeremy Smollar.
The position was built through three transactions: two earlier issuances to Marvin Smollar that were later transferred into the trust, and a January 29, 2026 pro-rata distribution from MedScience Research Group, Inc. The trust states it holds the shares solely for estate administration and intends to distribute all 2,226,280 shares under the trust instrument.
QHSLab, Inc. reported unaudited first quarter 2026 Integrated Service Program (ISP) revenue of approximately $370,000, up from $163,000 a year earlier, representing 127% year-over-year growth driven by expanding provider adoption of its recurring digital care model.
The company also launched Q-Connect GLP-1, an assessment and personalized health journeys program supporting patients using anti-obesity medications, including GLP-1 therapies, and broader cardiometabolic and behavioral health needs, extending its digital health platform for primary care and specialty practices.
QHSLab, Inc. reported a strong turnaround for fiscal 2025, with revenue rising to $2,691,741, about 26% higher than 2024. Growth was driven largely by its Integrated Service Program for primary care practices.
Gross profit increased to $1,810,849 and gross margin improved to 67.3%, showing a shift toward higher-margin digital health services. The company moved to net income of $457,417 from a prior-year net loss, helped by lower interest expense and a gain of about $1.15 million from extinguishing convertible debt.
QHSLab strengthened its balance sheet as cash rose to $636,157 and current liabilities fell from roughly $2.4 million to about $450,000 at year-end 2025. Integrated Service Program revenue grew 74% year-over-year to $1,121,134, while immunotherapy sales also increased, supporting a more diversified and scalable business model.
QHSLab, Inc. (USAQ) reports a small 2025 profit while warning that its ability to continue as a going concern is uncertain. The digital health and allergy-diagnostics company earned net income of $457,417 in 2025, helped by a one-time $666,000 gain from extinguishing debt, after a $259,239 loss in 2024.
Revenue rose to $2,691,741 in 2025 from $2,131,926 in 2024, driven by its QHSLab SaaS platform and AllergiEnd allergy products sold to independent primary care practices. The business still relies on external funding, taking $362,168 of loans and raising $499,998 of equity in 2025, and had $201,788 of notes and loans outstanding at year-end.
The company flags material weaknesses in internal controls due to limited staff and discloses significant regulatory, data-privacy and reimbursement risks tied to operating in heavily regulated healthcare and handling protected health information. As of March 30, 2026, QHSLab had 12 employees and 15,032,788 common shares outstanding; non‑affiliate holders owned 7,438,363 shares valued at $1,562,056 as of June 30, 2025.
QHSLab, Inc. Schedule 13G/A: Nicholas Peters reported beneficial ownership of 1,161,049 shares of common stock, representing 8.65% of the class. The filing states he holds both sole and shared voting power and dispositive power over 1,161,049 shares. The form is signed 02/25/2026.
QHSLab, Inc. reports a Schedule 13G showing beneficial ownership of 8.65% represented by 1,161,049 shares of Common Stock. The filing lists Nicholas Peters as the beneficial owner with sole and shared voting and dispositive power over 1,161,049 shares.
The filing is signed by Nicholas Peters and dated 02/09/2026.